Wei Yiting, Zhang Yunpeng, Li Pengcheng, Yan Chunguang, Wang Lixin
Department of Microbiology and Immunology, Medical School of Southeast University, 210009 Nanjing, Jiangsu Province, China.
BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, 210019 Nanjing, Jiangsu Province, China.
Int Immunopharmacol. 2023 Apr;117:109744. doi: 10.1016/j.intimp.2023.109744. Epub 2023 Feb 20.
Thymosin α-1 (Tα-1) is an immunomodulating polypeptide of 28 amino acids, which was the first peptide isolated from thymic tissue and has been widely used for the treatment of viral infections, immunodeficiencies, and especially malignancies. Tα-1 stimulates both innate and adaptive immune responses, and its regulation of innate immune cells and adaptive immune cells varies under different disease conditions. Pleiotropic regulation of immune cells by Tα-1 depends on activation of Toll-like receptors and its downstream signaling pathways in various immune microenvironments. For treatment of malignancies, the combination of Tα-1 and chemotherapy has a strong synergistic effect by enhancing the anti-tumor immune response. On the basis of the pleiotropic effect of Tα-1 on immune cells and the promising results of preclinical studies, Tα-1 may be a favorable immunomodulator to enhance the curative effect and decrease immune-related adverse events of immune checkpoint inhibitors to develop novel cancer therapies.
胸腺素α-1（Tα-1）是一种由28个氨基酸组成的免疫调节多肽，它是首个从胸腺组织中分离出的肽段，已被广泛用于治疗病毒感染、免疫缺陷，尤其是恶性肿瘤。Tα-1可刺激先天性和适应性免疫反应，在不同疾病状态下，其对先天性免疫细胞和适应性免疫细胞的调节作用有所不同。Tα-1对免疫细胞的多效性调节取决于在各种免疫微环境中Toll样受体及其下游信号通路的激活。对于恶性肿瘤的治疗，Tα-1与化疗联合使用可通过增强抗肿瘤免疫反应产生强大的协同作用。基于Tα-1对免疫细胞的多效性作用以及临床前研究取得的 promising results，Tα-1可能是一种理想的免疫调节剂，可增强免疫检查点抑制剂的疗效并减少免疫相关不良事件，从而开发新的癌症治疗方法。 （注：原文中“promising results”未翻译完整，可补充完整后再准确翻译，这里先按字面保留）
